DI BARTOLOMEO, MARIA CRISTINA
 Distribuzione geografica
Continente #
EU - Europa 949
NA - Nord America 492
AS - Asia 336
OC - Oceania 2
AF - Africa 1
Totale 1.780
Nazione #
US - Stati Uniti d'America 484
DE - Germania 464
GB - Regno Unito 194
CN - Cina 189
SE - Svezia 82
IT - Italia 77
SG - Singapore 56
IE - Irlanda 35
IN - India 28
HK - Hong Kong 18
RU - Federazione Russa 18
FR - Francia 16
FI - Finlandia 12
ID - Indonesia 12
UA - Ucraina 11
KR - Corea 10
BE - Belgio 8
CA - Canada 8
ES - Italia 8
DK - Danimarca 7
VN - Vietnam 7
JP - Giappone 6
NL - Olanda 6
NO - Norvegia 6
CH - Svizzera 2
HU - Ungheria 2
IR - Iran 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AU - Australia 1
EG - Egitto 1
GE - Georgia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PL - Polonia 1
TH - Thailandia 1
UZ - Uzbekistan 1
Totale 1.780
Città #
Frankfurt am Main 426
Southend 177
Chandler 86
Milan 46
Fairfield 38
Dublin 35
Ashburn 32
Beijing 26
Seattle 26
Singapore 26
Wilmington 26
Princeton 25
Cambridge 19
Houston 19
Dearborn 17
Woodbridge 17
Ann Arbor 16
Nanjing 15
Bengaluru 14
Hong Kong 13
Shanghai 13
New York 11
Phoenix 11
Jakarta 10
Des Moines 9
Brussels 8
Helsinki 8
Munich 8
Los Angeles 7
Shenyang 7
Jinan 6
Mountain View 6
Oslo 6
Santa Clara 6
Toronto 6
Grafing 5
Hangzhou 5
Hebei 5
Hyderabad 5
San Diego 5
Wuhan 5
Falls Church 4
Zhengzhou 4
Amsterdam 3
Central District 3
Changsha 3
Guangzhou 3
Kent 3
Lanzhou 3
Ningbo 3
Nuremberg 3
Taiyuan 3
Taizhou 3
Tianjin 3
Andover 2
Boardman 2
Budapest 2
Bühl 2
Chongqing 2
Eitensheim 2
Fremont 2
Fuzhou 2
Guadarrama 2
Hayamiya 2
Kingston Upon Thames 2
Molina de Segura 2
New Delhi 2
Quanzhou 2
Redwood City 2
Rho 2
Rome 2
Roxbury 2
Suzhou 2
Upper Marlboro 2
Xiamen 2
Zafra 2
Almere 1
Auckland 1
Baltimore 1
Basel 1
Berlin 1
Boston 1
Brentford 1
Central 1
Changchun 1
Chaozhou 1
Charlotte 1
Chicago 1
Duncan 1
Düsseldorf 1
Esslingen am Neckar 1
Fars 1
Gatchina 1
Giza 1
Groningen 1
Grünwald 1
Gunzenhausen 1
Habikino 1
Haikou 1
Hanoi 1
Totale 1.360
Nome #
Perioperative Bevacizumab-based Triplet Chemotherapy in Patients with Potentially Resectable Colorectal Cancer Liver Metastases 165
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan 164
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer 156
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors 153
Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer : challenging drug label to light up new hope 150
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer : a systematic review and meta-analysis 127
Maintenance Therapy with Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 126
Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen 125
A review on biomarkers for prediction of treatment outcome in gastric cancer 100
Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer 97
Transcriptional and epigenetic phenomena in peripheral blood cells of monozygotic twins discordant for Alzheimer’s disease, a case report 94
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series 87
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study 87
Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study 85
Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions 76
Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer : a systematic review and meta-analysis 69
Totale 1.861
Categoria #
all - tutte 5.277
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.277


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020159 0 0 0 22 9 25 25 8 30 26 8 6
2020/2021129 6 5 4 1 12 13 8 16 21 11 17 15
2021/2022229 17 18 17 8 12 20 11 8 19 32 16 51
2022/2023290 31 40 29 24 17 61 7 16 39 1 18 7
2023/2024519 9 11 17 22 73 21 63 63 31 61 71 77
2024/2025241 57 76 51 57 0 0 0 0 0 0 0 0
Totale 1.861